Abstract
Introduction Nottingham histological grade (NHG) is a well established prognostic factor in breast cancer histopathology. However, manual NHG assessment of biopsies is challenging and has a large inter-assessor variability with a large proportion being classified as NHG2 (intermediate grade). Here, we evaluate whether DeepGrade, a previously developed model for the risk stratification of resected tumour specimens, could be applied to risk-stratify biopsy specimens.
Methods A total of 11,943,905 tiles from 1171 whole slide images (WSIs) of preoperative biopsies from 897 patients diagnosed with breast cancer in Stockholm, Sweden, were included in this retrospective observational study. DeepGrade, a deep convolutional neural network model, was applied for classification of low and high risk tumours and evaluated against clinically assigned grades 1 and 3 using area under the operating curve (AUC). The prognostic value of the DeepGrade model in the biopsy setting was evaluated using time-to-event analysis.
Results The DeepGrade model classified resected tumour cases with grades NHG1 and NHG3 using only biopsy specimens with an AUC of 0.903 (95% CI: 0.88;0.93). The model could also classify the biopsy NHG (1 and 3) assessed on the biopsy of 186 patients with an AUC of 0.959 (95% CI: 0.93; 0.99). Furthermore, out of the 434 NHG2 tumours, 255 (59%) were classified as DeepGrade2-low, and 179 (41%) were classified as DeepGrade2-high. Using a multivariable Cox proportional hazards model the hazard ratio between low- and high-risk groups was estimated as 2.01 (p-value = 0.036).
Conclusions DeepGrade could predict the resected tumour grades NHG1 and NHG3 using only the biopsy specimen and sub-classify grade 2 tumours into low and high risks. The results demonstrate that the DeepGrade model can provide decision support for biopsy grading, and potentially provide decision support in the clinical setting to identifying high-risk tumours based on preoperative breast biopsies, thus improving information available for clinical treatment decisions.
Competing Interest Statement
The authors declare the following financial interests or personal relationships which may be considered as potential competing interests: J.H. has obtained speaker's honoraria or advisory board remunerations from Roche, Novartis, AstraZeneca, Eli Lilly and MSD. J.H. has received institutional research grants from Cepheid, Roche and Novartis. M.R. and J.H. are shareholders of Stratipath AB. Y.W., P.W., E.K., and S.R. are partially employed by Stratipath AB. All remaining authors have declared no competing interests.
Funding Statement
This project was supported by funding from the Swedish Research Council under the frame of ERA PerMed (ERAPERMED2019-224 - ABCAP), Swedish Research Council, VINNOVA (SwAIPP project), Swedish Cancer Society, Karolinska Institutet (Cancer Research KI; StratCan), MedTechLabs, Swedish e-science Research Centre (SeRC), Stockholm Region, Stockholm Cancer Society and Swedish Breast Cancer Association
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Swedish Ethics Review Authority (Etikprovnings myndigheten) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
